Amgen (AMGN): Phase 3 romosozumab Answers Some Questions - BMO

September 20, 2016 9:16 AM EDT
Get Alerts AMGN Hot Sheet
Price: $143.45 +2.03%

Rating Summary:
    17 Buy, 14 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade AMGN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating Amgen (NASDAQ: AMGN) after Amgen released additional results from its Phase 3 study of romosozumab, which provided a tangible explanation for the trial not achieving a key secondary endpoint of reduction in non-vertebral fractures. A lack of visibility into how this will translate into a label claim and compelling data for Radius's abaloparatide could limit peak sales to $700mn (assuming 1.0% peak global market share).

Looking ahead, the analyst sees the FOURIER CV outcomes trial (data 1Q17) as the most important catalyst for AMGN shares. No change to the price target of $190.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $171.38 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment